SCHEMBL5457579

SCHEMBL5457579

Fc1ccc(-c2nn3c(Cl)cccc3c2-c2ccnc(-c3ccccc3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 6/20 0.61
GSK3B P49841 12/20 0.48
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ATM Q13315 1/20 0.40
CDK2 P24941 2/20 0.40
MAPT P10636 1/20 0.39
PTK2B Q14289 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CDK1 P06493 1/20 0.38
CDK4 P11802 1/20 0.38
CCNB1 P14635 1/20 0.38
CCNA2 P20248 1/20 0.38
CCND1 P24385 1/20 0.38
CDK7 P50613 1/20 0.38
CCNH P51946 1/20 0.38
EGFR P00533 1/20 0.38
RAF1 P04049 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459561 0.83 MAPK14 (0.58) MAPK14GSK3BADORA2AADORA2BADORA1
SCHEMBL5449758 0.82 MAPK14 (0.57) MAPK14GSK3B
SCHEMBL5459543 0.79 MAPK14 (0.54) MAPK14GSK3BCDK4
SCHEMBL5875540 0.79 MAPK14 (0.60) MAPK14GSK3BEGFRRAF1ADORA3
SCHEMBL5461798 0.78 MAPK14 (0.53) MAPK14GSK3BCDK4
SCHEMBL5452937 0.77 MAPK14 (0.52) MAPK14GSK3B
SCHEMBL5457469 0.76 MAPK14 (1.00) MAPK14GSK3BEGFRRAF1ADORA3
SCHEMBL6184720 0.73 GSK3B (0.65) GSK3BCDK2
SCHEMBL5455132 0.72 MAPK14 (0.48) MAPK14GSK3BKMT2AMEN1ATM
Hydrazine SCHEMBL3298022 0.72 KMT2A (0.68) KMT2AMEN1NPC1RAB9AATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1377573-B1 PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2005-07-27 EP claimed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-7163940-B2 Pyrazolopyridinyl pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-01-16 US disclosed
US-7163940-B2 Pyrazolopyridinyl pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-01-16 US disclosed
EP-1377573-B1 PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2005-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287721-A1 Pyrazolopyridinyl pyridine CYP3A5, CYP2C19, CYP3A4 MAPK14 2533/4885GSK3B 2943/4885KMT2A 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.